Literature DB >> 34424493

Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.

Daichi Sato1, Kunihiko Moriya2, Tomohiro Nakano1, Chihiro Miyagawa1, Saori Katayama1, Hidetaka Niizuma1, Yoji Sasahara1, Shigeo Kure1.   

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ATM (A-T mutated) gene, which encodes a protein kinase that has a major role in the cellular response to DNA damage. Approximately, 10% of A-T patients develop lymphoid malignancies. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported, and cancer treatment in A-T is extraordinarily difficult, needing careful monitoring and individualized protocols. We report the case of a 12-year-old girl with A-T diagnosed at the age of 3 in association with IgA deficiency and recurrent pulmonary infections. Sanger sequencing revealed compound heterozygosity of the ATM gene, which bore two novel mutations. At the age of 12, she developed stage IV T-cell/histiocyte-rich large B-cell lymphoma. The tumor was resistant to chemotherapy, and she unfortunately died of cardiac insufficiency and multiple organ failure induced by rapid progression of the disease. The treatment approach for children with A-T and advanced-stage B-non-Hodgkin lymphoma must be refined.
© 2021. Japanese Society of Hematology.

Entities:  

Keywords:  Ataxia–telangiectasia; Chemotherapy; T-cell/histiocyte-rich large B-cell lymphoma

Mesh:

Substances:

Year:  2021        PMID: 34424493     DOI: 10.1007/s12185-021-03203-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

1.  Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity.

Authors:  Gertjan J Driessen; Hanna Ijspeert; Corry M R Weemaes; Ásgeir Haraldsson; Margreet Trip; Adilia Warris; Michiel van der Flier; Nico Wulffraat; Mijke M M Verhagen; Malcolm A Taylor; Menno C van Zelm; Jacques J M van Dongen; Marcel van Deuren; Mirjam van der Burg
Journal:  J Allergy Clin Immunol       Date:  2013-04-06       Impact factor: 10.793

Review 2.  Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group.

Authors:  Simon Bomken; Jutte van der Werff Ten Bosch; Andishe Attarbaschi; Chris M Bacon; Arndt Borkhardt; Kaan Boztug; Ute Fischer; Fabian Hauck; Roland P Kuiper; Tim Lammens; Jan Loeffen; Bénédicte Neven; Qiang Pan-Hammarström; Isabella Quinti; Markus G Seidel; Klaus Warnatz; Claudia Wehr; Arjan C Lankester; Andrew R Gennery
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.